Zobrazeno 1 - 10
of 146
pro vyhledávání: '"A C, Dalgarno"'
Autor:
Gabriel Monteiro da Silva, Jennifer Y. Cui, David C. Dalgarno, George P. Lisi, Brenda M. Rubenstein
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract This paper presents an innovative approach for predicting the relative populations of protein conformations using AlphaFold 2, an AI-powered method that has revolutionized biology by enabling the accurate prediction of protein structures. Wh
Externí odkaz:
https://doaj.org/article/7f2e13d81e424a5eb5b8c27b36adc5cd
Autor:
Gabriel Monteiro da Silva, Jennifer Y. Cui, David C. Dalgarno, George P. Lisi, Brenda M. Rubenstein
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/0eb397448ffd43329fab78f7c063809e
Autor:
Wei-Sheng, Huang, Feng, Li, Yongjin, Gong, Yun, Zhang, Willmen, Youngsaye, Yongjin, Xu, Xiaotian, Zhu, Matthew T, Greenfield, Anna, Kohlmann, Paul M, Taslimi, Angela, Toms, Stephan G, Zech, Tianjun, Zhou, Biplab, Das, Hyun G, Jang, Meera, Tugnait, Yihua E, Ye, Francois, Gonzalvez, Theresa E, Baker, Sara, Nadworny, Yaoyu, Ning, Scott D, Wardwell, Sen, Zhang, Alexandra E, Gould, Yongbo, Hu, Weston, Lane, Robert J, Skene, Hua, Zou, Tim, Clackson, Narayana I, Narasimhan, Victor M, Rivera, David C, Dalgarno, William C, Shakespeare
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 80:129084
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this subset of mutants is generally resistant to mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36257c29b5ae4b54e2d345df53177fd7
https://doi.org/10.1016/j.bmcl.2022.129084
https://doi.org/10.1016/j.bmcl.2022.129084
Autor:
Wei-Sheng Huang, Sara Nadworny, Narayana Narasimhan, Charles J. Eyermann, David C. Dalgarno, Victor M. Rivera, William C. Shakespeare
Publikováno v:
Cancer Research. 82:3342-3342
Introduction: EGFR activating mutations are observed in 10-50% of NSCLC patients and the common mutations (L858R [L] and exon 19 deletions [D]) are initially sensitive to first-, second-, and third-generation EGFR inhibitors (eg erlotinib [1G], afati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b478b2d980afa91a4eec642fa30c3f7
https://doi.org/10.1158/1538-7445.am2022-3342
https://doi.org/10.1158/1538-7445.am2022-3342
Autor:
Tomi K. Sawyer, Regine S. Bohacek, Chester A. Metcalf III, William C. Shakespeare, Yihan Wang, Raji Sundaramoorthi, Terence Keenan, Surinder Narula, Manfred Weigele, David C. Dalgarno
Publikováno v:
BioTechniques, Vol 34, Iss 6S, Pp S2-S15 (2003)
Externí odkaz:
https://doaj.org/article/2a7a4be570f14a5eb30fe9249ca4314e
Autor:
David C. Dalgarno, Mengrou Lu, Justin R. Pritchard, Victor Rivera, William C. Shakespeare, Wei-Sheng Huang
Publikováno v:
Cancer Research. 81:1292-1292
Introduction: GIST is the most common sarcoma of the GI tract, with most cases driven by activating mutations in KIT Ex11 or Ex9. Prognosis is poor for patients whose tumors progress following first-line (1L) imatinib treatment, despite availability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5390064913679f2b251b3b095dfe80
https://doi.org/10.1158/1538-7445.am2021-1292
https://doi.org/10.1158/1538-7445.am2021-1292
Autor:
Shuangying Liu, Xiaotian Zhu, Angela Toms, Yongjin Xu, David C. Dalgarno, Rory Dodd, Lois Parillon, Yihan Wang, Scott Wardwell, Tim Clackson, Jiwei Qi, Anna Kohlmann, Yaoyu Ning, Hyun Gyung Jang, Xiaohui Lu, Lisi Cai, Qurish K. Mohemmad, Rongsong Xu, Dong Zou, Sen Zhang, William C. Shakespeare, Timothy A. Dwight, Narayana I. Narasimhan, Qihong Xu, Rana Anjum, Lauren Moran, Tianjun Zhou, Frank Wang, Mathew Thomas, Wei-Sheng Huang, Jeffrey A. Keats, Feng Li, Jan Romero, Victor M. Rivera
Publikováno v:
Journal of medicinal chemistry. 59(10)
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::625d183379f1d6b062d2872fda27b944
https://pubmed.ncbi.nlm.nih.gov/27144831
https://pubmed.ncbi.nlm.nih.gov/27144831
Autor:
Lauren Moran, Wei-Sheng Huang, Yaoyu Ning, Dong Zou, Scott Wardwell, Emily Y. Ye, Frank Wang, Rachel M. Squillace, Lindsey W. Eichinger, Victor M. Rivera, Jeff Keats, Sen Zhang, William C. Shakespeare, Yihan Wang, Sara Nadworny, Shuangying Liu, Tianjun Zhou, Youngchul Song, Xiaotian Zhu, Tim Clackson, David Miller, Hyun Gyung Jang, Narayana I. Narasimhan, Rana Anjum, David C. Dalgarno, Qurish K. Mohemmad, Juan J. Miret
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(22)
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a954184cf0503cf7aa96ae269a34c3cb
https://pubmed.ncbi.nlm.nih.gov/27780853
https://pubmed.ncbi.nlm.nih.gov/27780853
Autor:
Sen Zhang, Tim Clackson, David C. Dalgarno, Victor M. Rivera, Xiaotian Zhu, William C. Shakespeare, Scott Wardwell, Narayana I. Narasimhan, Lauren Moran, Qurish K. Mohemmad, Jeffrey A. Keats, Rana Anjum, Yaoyu Ning, Juan J. Miret, Yihan Wang, Frank Wang
Publikováno v:
Chemical Biology & Drug Design
Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizotinib, a dual MET/ALK inhibitor, has demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f1b2a369ba7aad684338c137f1aa03
https://doi.org/10.1111/j.1747-0285.2011.01239.x
https://doi.org/10.1111/j.1747-0285.2011.01239.x
Autor:
Xiaotian Zhu, Dong Zou, Chester A. Metcalf, Raji Sundaramoorthi, Frank Wang, Feng Li, Jan Romero, John Iuliucci, Lois Commodore, Shuangying Liu, Wei-Sheng Huang, Lisi Cai, Qihong Xu, Jeff Keats, Tim Clackson, David C. Dalgarno, Joseph Snodgrass, Jiwei Qi, Yihan Wang, Victor M. Rivera, Mathew Thomas, Ingrid Chen, Tianjun Zhou, Yaoyu Ning, David Wen, Tomi K. Sawyer, Karin Russian, William C. Shakespeare, Marc I Broudy, Scott Wardwell
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:3743-3748
Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML. In this study, we explored a nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a38549836ca328c6bb343c0b0ec0da
https://doi.org/10.1016/j.bmcl.2011.04.060
https://doi.org/10.1016/j.bmcl.2011.04.060